Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 7NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Adrenocortical Carcinoma 2

Interventions

cixutumumab 2cabozantinib 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Mitotane 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Cisplatin 2tipifarnib 1sodium thiosulfate 1gossypol acetic acid 1entinostat 1cemiplimab 1Vincristine 1Tamoxifen 1Ritonavir 1Oxaliplatin 1Nivolumab 1Microscopy, Electron 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Floxuridine 1Etoposide 1Dichlorodiphenyldichloroethane 1Dexamethasone 1Cytoreduction Surgical Procedures 1CYT-6091 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Adrenocortical Carcinoma × Mitotane × Clear all
NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 17 charts
Endocrine

Adrenocortical Carcinoma

NCT00001339 2008-03-04

A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡